APhA continues to advocate that CMS and other payers take immediate action to provide adequate and appropriate payment for pharmacist test to treat services.
Act now: Tell Congress payment for pharmacist prescribing of Paxlovid is critical
Pharmacists now have the authority to prescribe Paxlovid for the treatment of mild to moderate COVID-19 disease under certain conditions. While updating the emergency use authorization (EUA) was a huge step forward, there is no current federal policy providing coverage for the associated clinical services required for pharmacist prescribing.
Use our prewritten, editable advocacy alert to ask your U.S. representatives to contact HHS and CMS to identify a payment pathway to reimburse pharmacists for their prescription of Paxlovid.